Association between antithrombotic treatment and outcomes at 1-year follow-up in patients with atrial fibrillation: the EORP-AF General Long-Term Registry
Why the study?
Stroke prevention in AF has radically changed with increasing NOAC use, creating a need for contemporary European thromboprophylaxis data.
Does antithrombotic therapy improve 1-year outcomes in patients with atrial fibrillation?
Population
9663 patients with AF in the EORP-AF General Long-Term Registry
Comparison
Different antithrombotic regimens (NOACs, VKA, antiplatelets, combinations) vs no antithrombotic therapy
Design
Prospective observational registry
Follow-up
1 year
Authors
Discussion
Loading...
Member takes
Implication
Supports OAC in AF; extends registry data but leaves causal benefit open pending RCTs.
Structured PICO
Does antithrombotic therapy improve 1-year outcomes in patients with atrial fibrillation?
P
Population
9,663 patients with atrial fibrillation from the European EORP-AF General Long-Term Registry
I
Intervention
Antithrombotic therapy (NOACs, VKA, antiplatelets, or combination)
C
Comparator
No antithrombotic therapy or comparison among different antithrombotic regimens
O
Outcome
Stroke, any thromboembolic event, haemorrhagic events, cardiovascular death, and all-cause death at 1-year follow-uphard clinical
In a large European registry of AF patients, use of NOACs or VKAs was associated with lower risks of thromboembolic events and mortality at 1 year.
Cite This Study
Boriani et al. (2019) studied this question.